The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication. The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose mea

Global healthcare is a $12 trillion market carrying a 34-million worker shortage, yet healthtech captured just 5% of the $712 billion in global venture capital deployed in the first half of 2026. That gap, a trillion-dollar industry still treated as a rounding error by the venture industry, is the starting point for everything else here. We at Verge HealthTech Fund have always talked about how healthcare should transform from “sick-care” to “health + care.”

Direct macro intelligence synthesized from main-stage keynotes and private allocator dialogues at the seventh Longevity Investors Conference in Gstaad. What Top Allocators at the Longevity Investors Conference Are Quietly Rotating Out Of—and the Sovereign Infrastructure Replacing It.

Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion. Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.

On the Science, Art, and Soul of Wellness: Healthspan Evolution, Clinical Convergence, and the 20-Year Horizon

Capital follows vitality. Here is where the global longevity, investment, and high-performance ecosystem meets next.

The metrics that have defined elite human performance for the past decade are quietly becoming baseline commodities. The global vanguard has spent years meticulously quantifying the vessel—mapping heart rate variability like financial charts, tracking sleep architecture, and measuring glycemic responses to environmental inputs. Yet, as the physical domain becomes increasingly optimized, a profound realization is taking root among those who operate at the absolute limits of pe

The border between community endurance and ultra-luxury portfolios has officially dissolved. LVMH Capital, operating through its premier consumer-focused private equity vehicle L Catterton, has entered advanced exclusive negotiations to acquire a dominant majority stake in the global fitness racing phenomenon, HYROX. The deal, which negotiates terms with Switzerland-based sports marketing and rights giant Infront Sports & Media AG, commands a striking market valuation floor b

The 12 Hallmarks of Aging have become one of the most influential frameworks in longevity science. As longevity evolves into an emerging asset class—shaping healthcare, biotechnology, real estate, hospitality, and investment strategies—the Hallmarks of Aging provide a scientific lens for understanding what ultimately determines healthspan, brainspan, and performancespan. Yet their significance extends beyond biology.

For decades, the luxury skincare industry operated as a high-margin consumer category—a commoditized market built on aesthetic masking. That era has concluded. We are currently witnessing a decisive migration of R&D capital into a new domain: Cellular Longevity. This is not a shift in marketing; it is a fundamental re-engineering of the industry's value chain, moving from cosmetic maintenance to high-barrier biological intervention. The market has bifurcated. On one side,

Switzerland hasn't just become a family office fortress; it has become the global headquarters for the "Biological Balance Sheet." The headlines suggest that Swiss banking secrecy ended in 2018. The reality? Capital is flooding in faster than ever. But a more profound shift is occurring beneath the surface. Families are no longer establishing $4B+ single-family offices (SFOs) merely to manage portfolios. They are anchoring themselves in Switzerland to manage the most criti

When L Catterton, the private equity fund backed by LVMH and Groupe Arnault, invested up to US$5 million in WTHN, the New York brand modernizing Traditional Chinese Medicine (TCM), they were not merely diversifying a portfolio. They were signaling the next era of luxury: East-meets-West longevity.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.

In East Asia, longevity is not merely a sector—it is a strategic ethos. From the timeless streets of Tokyo, to the innovation corridors of Seoul, across Beijing’s vast horizons, through the vibrant pulse of Hong Kong, and the refined neighborhoods of Taipei, wellness is architected into daily life, technology, and urban infrastructure. The region offers a canvas where scale, sophistication, and exclusivity converge, producing opportunities as investable as they are visionary.